{
    "Patient": {
        "Name": "Troy Smith",
        "DOB": "1987-08-02",
        "Sex": "Male",
        "Caseno": "4816",
        "Diagnosis": "Large cell carcinoma",
        "Physician": "Dr. Cindy Holmes"
    },
    "specimen information": {
        "primary_tumor_site": "Lung",
        "specimen_site": "Mediastinal lymph nodes",
        "specimen_ID": "4476",
        "CollectedDate": "2023-09-01",
        "ReceivedDate": "2023-09-01",
        "Pathological Diagnosis": "Left breast, central, 12:00, suspicious mass, 12-gauge core needle biopsy: Infiltrating moderately-differentiated mammary carcinoma, grade 2, Nottingham score 6 (architectural grade 3, nuclear grade 2, mitotic figures 1).",
        "Dissection Information": "Molecular testing of this specimen was performed after harvesting of targeted tissues with an approved manual microdissection technique. Candidate slides were examined under a microscope and areas containing tumor cells (and separately normal cells, when necessary for testing) were circled. A laboratory technician harvested targeted tissues for extraction from the marked areas using a dissection microscope."
    },
    "Results with Therapy association": [
        {
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 3+, 100%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine",
                "therapy",
                "everolimus"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 2+, 95%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine therapy"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "TMB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "17 m/Mb High",
            "Therapy association": [
                "BENEFIT",
                "pembrolizumab"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "ERBB2",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative | 0",
            "Therapy association": [
                "LACK OF BENEFT",
                "trastuzumab",
                "ado-trastuzumab emtansine",
                "pertuzumab",
                "fam-trastuzumab deruxtecan-nxki",
                "lapatinib",
                "neratinib",
                "tucatinib"
            ],
            "Biomarker_level": "level 1"
        }
    ],
    "Relevant Biomarkers": [
        {
            "BioMarker": "NRAS",
            "Method": "Seq",
            "Analyte": "RNA-Tumor",
            "Result": "Mutation not detected"
        },
        {
            "BioMarker": "PR",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 1+, 51%"
        },
        {
            "BioMarker": "CDC73",
            "Method": "Seq",
            "Analyte": "DNA-Tumor",
            "Result": "Fusion not detected"
        },
        {
            "BioMarker": "PD-L1(SP142)",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 1+, 17%"
        },
        {
            "BioMarker": "SDHA",
            "Method": "Seq",
            "Analyte": "DNA-Tumor",
            "Result": "Fusion not detected"
        },
        {
            "BioMarker": "PD-L1(SP142)",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 2+, 42%"
        },
        {
            "BioMarker": "Mismatch repair status",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 1+, 32%"
        }
    ],
    "Genomic Signatures": [
        {
            "BioMarker": "Microsatellite instability",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High"
        },
        {
            "BioMarker": "Tumor mutational burden",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "17 mutations/Mb High"
        },
        {
            "BioMarker": "Genomic loss of heterozygosity (LOH)",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High - 19% of tested genomic segments exhibit LOH"
        }
    ],
    "Genes Tested with Pathogenic Alterations": [
        {
            "Gene": "NTRK1",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Benign",
            "Protien Alteration": "p.P904L",
            "Exon": 18,
            "DNA Alteration": "c.2711C>T",
            "Allele Frequency %": "1.44"
        },
        {
            "Gene": "MET",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Benign",
            "Protien Alteration": "p.Y646X",
            "Exon": 2,
            "DNA Alteration": "c.1937A>C",
            "Allele Frequency %": "16.57"
        },
        {
            "Gene": "SRSF2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Benign",
            "Protien Alteration": "p.Y736fs*4",
            "Exon": 4,
            "DNA Alteration": "c.2207_2212delinsTAGATTC",
            "Allele Frequency %": "12.54"
        },
        {
            "Gene": "HSD3B1",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Benign",
            "Protien Alteration": "p.G935R",
            "Exon": 2,
            "DNA Alteration": "c.1849G>T",
            "Allele Frequency %": "9.91"
        }
    ],
    "Gene variants of unknown significance": [
        {
            "Gene": "MPL",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.P98S",
            "Exon": 3,
            "DNA Alteration": "A",
            "Allele Frequency %": "6.73"
        },
        {
            "Gene": "HBB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.G469S",
            "Exon": 3,
            "DNA Alteration": "c.1799_1800delinsAA",
            "Allele Frequency %": "20.76"
        },
        {
            "Gene": "ABL1",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.R222C",
            "Exon": 20,
            "DNA Alteration": "c.866C>A",
            "Allele Frequency %": "3.05"
        },
        {
            "Gene": "PIK3CA",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.G607V",
            "Exon": 4,
            "DNA Alteration": "c.1792C>T",
            "Allele Frequency %": "6.26"
        },
        {
            "Gene": "ERCC2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.A322T",
            "Exon": 14,
            "DNA Alteration": "c.239C>G",
            "Allele Frequency %": "9.19"
        }
    ],
    "Immunohistochemistry results": [
        {
            "Biomarker": "ERBB2",
            "Result": "Negative| 2+, 49%"
        },
        {
            "Biomarker": "PD-L1(SP142)",
            "Result": "Positive| 1+, 50%"
        },
        {
            "Biomarker": "PR",
            "Result": "Negative| 3+, 36%"
        },
        {
            "Biomarker": "AR",
            "Result": "Positive| 1+, 55%"
        }
    ],
    "Genes Tested with indeterminate results": [
        "PIK3CA",
        "XPC",
        "PTPN11",
        "SMO",
        "B2M",
        "SRSF2"
    ],
    "Chemotherapy clinical trials": [
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti inflammatory agents",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "aspirin"
            ]
        }
    ],
    "Targeted therapy clinical trials": [
        {
            "Drug class": "Akt inhibitors",
            "Biomarker": "ARID1A",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "MK-2206",
                "ipataserib"
            ]
        },
        {
            "Drug class": "immunomodulatory agents",
            "Biomarker": "TMB",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "avelumab",
                "atezolizumab",
                "durvalumab",
                "ipilimumab",
                "nivolumab",
                "pembrolizumab"
            ]
        },
        {
            "Drug class": "PARP inhibitors",
            "Biomarker": "NBN",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "BGB-290",
                "BMN-673",
                "olaparib",
                "rucaparib",
                "talazoparib"
            ]
        },
        {
            "Drug class": "Akt/mTor inhibitors",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "BYL719",
                "MK-2206",
                "ipataserib",
                "everolimus",
                "temsirolimus"
            ]
        }
    ]
}